Massive pulmonary embolism (MPE) is one of the potentially reversible causes of cardiac arrest and pulseless electrical activity. At present, a fear of lethal haemorrhage makes thrombolytic therapy prohibitive during cardiopulmonary resuscitation. Blood hypercoagulability in autoimmune disorders (such as autoimmune haemolytic anaemia) carries a risk of MPE. Prompt diagnosis is critical for timely thrombolytic intervention. We reported a 23-year-old female with 10 years medical history of autoimmune haemolytic anaemia developed cardiac arrest in our emergency intensive care unit. Electrocardiogram and echocardiogram findings indicated the possibility of MPE, so fibrinolytic therapy with alteplase was administered along with prolonged cardiopulmonary resuscitation. Her neurological recovery was generally good, and no major bleeding occurred. MPE was confirmed by computed tomography pulmonary angiography afterwards. We regard that once there is presumptive diagnosis of MPE, initiating early thrombolysis during cardiopulmonary resuscitation may be considered. 
Introduction
The prognosis of cardiac arrest is dismal, whether or not the patient is hospitalised, with survival rates of about 15% and 8%, respectively. 1, 2 These figures are even worse if nearly full recovery (i.e., no irreversible neurologic impairment) is stipulated. One common attributable aetiology of cardiac arrest events is thromboembolic disease, such as massive pulmonary embolism (MPE) and acute myocardial infarction. 3 Autoimmune diseases, particularly autoimmune haemolytic anaemia (AIHA), are associated with blood hypercoagulability, so care must be taken in this setting to prevent fatal thromboembolism. 4 During cardiopulmonary resuscitation (CPR), systemic thrombolysis is a controversial therapeutic approach due to fear of potentially lethal haemorrhage and it had been labelled as relative contraindication of thrombolysis in prolonged CPR. Current advanced cardiac life support (ACLS) guidelines maintain that evidence is still insufficient to recommend or discourage use of thrombolytic drugs during CPR, although empiric fibrinolytic therapy may be considered if PE is implicated. 5 Reported herein is a successful resuscitation, by the administration of alteplase (a recombinant tissue plasminogen activator) in a patient with clinical pulmonary embolism complicating cardiac arrest. Based on presumptive clinical evidence of MPE (due to AIHA), fibrinolytic was delivered with prolonged CPR. This scenario highlights the importance to achieve a clinical diagnosis of aetiology during resuscitation of patients with cardiac arrest.
Case
A 23-year-old woman presented to our emergency department (ED) with complaints of chills and fever for two days after being caught in the rain. She also had vomited twice (with black colour fluid), experiencing chest discomfort and light-headedness but no coughing, expectoration, or abdominal pain. Her vital signs were as follows: temperature 38.3°C; heart rate 135 beats per minute, respiratory rate 25/min; and blood pressure 122/81 mmHg. In addition, she had 10 years history of AIHA (untreated at the time) and 3 years history of bronchial asthma, on regular Seretide. She denied smoking and alcohol abuse and had no history of hypertension or diabetes.
Physical examination revealed tachycardia, tachypnoea, and shortness of breath, without crackles or wheeze. No abdominal tenderness, rebound tenderness, or rigidity was evident, and the lower extremities were not overtly oedematous. Her chest X-ray was normal. Ultrasound of both upper and lower extremities showed no evidence of deep vein thrombosis (DVT), despite a moderate risk as determined by Well's criteria for pulmonary embolism (PE). Sinus tachycardia with heart 148/min was noted on electrocardiogram (ECG) ( Figure 1A ).
Initial blood analysis (in ED) showed the following: haemoglobin 6.7 g/dl; reticulocytes 6%, white cell count 39 × 10 9 /L; neutrophils 73.8%; platelet count 224 × 10 9 /L; APTT 45 seconds; international normalisation ratio (INR) 1.5; D-dimer 9.8 µg/ml (normal range 0-0.5 µg/ml); C-reactive protein 101.2 mg/L; procalcitonin 1.2 ng/mL; and lactic acid 3.5 mmol/L. Direct and indirect Coombs tests (anti-IgG) were positive, and occult blood testing of the feces was markedly positive. Arterial blood gas on a nasal cannula tube with oxygen flow at 5 L/min revealed a PaO 2 /FiO 2 of 250 mmHg, pH 7.444, PaCO 2 35.9 mmHg and HCO 3 − 23 mmol/L.
The patient was admitted into emergency intensive care unit, with primary diagnoses of suspected PE, AIHA, and severe sepsis. About 4 hours after admission, she suddenly developed shock and subsequently progressed to cardiac arrest. CPR was started in a timely manner. A 12-lead ECG recorded briefly before cardiac arrest demonstrated sinus tachycardia, with incomplete right bundle-branch block and T inversion in precordial leads V1-4 ( Figure 1B ). S I Q III T III was evident.
Echocardiogram displayed right ventricular dilatation and moderate pulmonary hypertension, without pericardial effusion.
After a 20-min period of consistent CPR, a refractory pulseless electrical activity (PEA) occurred. MPE or acute myocardial infarction (AMI) was considered to potentially explain ECG and echocardiogram findings, so use of a thrombolytic agent was elected. A 5-mg bolus of alteplase was then delivered intravenously, followed by a continuous infusion (45 mg) over the next hour. A reduced dose was administered and the dosage was based on body weight and potential bleeding risk. CPR was continued for another 55 minutes, until return of spontaneous circulation was achieved. Computed tomography pulmonary angiography (CTPA) and cerebral CT were performed subsequently. MPE was apparent bilaterally (Figure 2 ), without obvious intracranial haemorrhage. The patient regained consciousness 6 hours after successful resuscitation. No neurologic deficit was evident, nor was the existing gastrointestinal haemorrhage aggravated. Unfortunately, she succumbed 5 weeks later as a consequence of the multiple organ dysfunction induced by severe tissue infection.
Cardiac arrest with pulseless electrical activity is generally attributable to hypovolaemia, hypoxia, hydrogen ion acidosis, hypo-/hyperkalaemia, and hypothermia (5 H's) or tension pneumothorax, tamponade, cardiac toxins, pulmonary thrombosis, and coronary thrombosis (5 T's). AMI was of major concern in this patient, as suggested by new ST-segment elevation on ECG, elevated troponin I blood level, abnormality of ventricular contraction, and demonstrable stenosis by coronary arteriography. Clearly, PE may be accompanied by myocardial ischaemia, owing in part to augmented right ventricular (RV) strain.
Discussion
The prognosis of cardiac arrest (CA) is dismal. It has been debated whether thrombolysis is warranted during CPR, given its potential benefits in instances of MPE or AMI. [6] [7] [8] The timing of such therapy is another key issue. In CPR of longer duration, haemorrhagic complications and mortality stand ostensibly may rise; but because the prognosis of CA is so poor, treatment should be aggressive, including possible use of fibrinolytic agents. We have found only a few case reports involving thrombolysis during extended CPR of patients with MPE. To our best knowledge, these accounts failed to address the impact of a hypercoagulable state under stress or during CPR. Nevertheless, Bailen et al did offer thrombolytic strategies for CA due to MPE. 9 Fibrinolytic targeting of a single large occlusive thrombus and microvascular thrombi was one approach. Another called for reduction of blood viscosity, reversing a no-flow phenomenon to protect the brain.
After CA, intravascular fibrin deposition and thrombus formation are ongoing throughout the entire microcirculation, generating significant activation of the coagulation cascade. However, endogenous fibrinolysis is not commensurate under these circumstances. Thrombolysis may thus improve microcirculatory dynamics overall, especially in the lungs.
Factors predisposing to venous thromboembolism (VTE) include but are not limited to hip or leg fracture, major trauma/surgery, chemotherapy, malignancy, pregnancy/postpartum conditions, thrombophilia, and prolonged immobility. Two large retrospective studies have indicated that autoimmune diseases (including AIHA) are associated with hypercoagulable states or thrombophilia. As such, the risk of subsequent VTE is heightened by patient immobilisation and inflammatory activity. 4, 10 Disturbed coagulation, endothelial injur y, and thrombosis typically accompany severe sepsis, brought on by bacterial products and pro-inflammator y cytokines. A thromboembolic event is then more likely in the setting of AIHS or severe sepsis.
Some clinical characteristics of this patient were highly suspicious of PE at presentation (prior to CTPA confirmation), such as respiratory distress, documented CA, younger age (<65 years), ECG changes, PEA episode, and echocardiogram results. All of the above are corroborated by an earlier report. 12 The ECG changes are linked to modifications in RV pressure load, leading to alterations in right-sided cardiac conduction. A combination of sinus tachycardia and T wave inversion in precordial leads has recently been identified as the most common sign of RV strain. 13 Right bundle branch block is also thought to be a marker for obstruction of the main pulmonary trunk.
Likewise, the occurrence of PEA (especially pseudo-PEA) during CPR is suggestive of PE. Pseudo-PEA is usually caused by hypovolaemia, tachydysrhythmias, decreased cardiac contractility or obstructions to circulation, such as tamponade, tension pneumothorax, and PE.
14 Successful treatment depends on early identification and immediate correction of potentially reversible aetiologies.
One may question whether an ultrasound study that is negative for DVT constitutes sufficient grounds for excluding PE. In reviewing the epidemiology of DVT and PE, Henzler et al found that DVT of the lower limbs could not be documented in about 30% of patients with PE. 15 With respect to exclusion of PE based on haemorrhage, a recent report further shows that the risk of DVT or PE did not decline with acquired coagulopathy. 16 However, it was concluded t h a t t h e u t i l i t y o f r o u t i n e p h a r m a c o l o g i c thromboprophylaxis for these patients remained uncertain.
As current guidelines for antithrombotic therapy and prevention of thrombosis specify, decisions on prophylaxis in nonsurgical patients should be made after considering risk factors for thrombosis and bleeding, clinical context, and values/preferences of patients. 17 Low-molecular weight heparin or unfractionated heparin may be prescribed for prophylaxis or treatment of VTE. However, thrombotic and bleeding risks may coexist, as in our patient. We did not initiate antithrombotic therapy early-on (in ED) due to active gastrointestinal bleeding.
Compared with other thrombolytic agents, such as streptokinase, urokinase, tenecteplase and reteplase, alteplase is the most widely, based on the proven benefit of a relatively brief infusion. This agent is indicated for treatment of MPE accompanied by unstable haemodynamic status.
18,19

Conclusion
A medical history of autoimmune disease poses a risk of PE, and potential aetiologies of CA (such as this) should be investigated. A therapeutic strategy that utilises alteplase may be initiated early during cardiopulmonar y resuscitation, once there is presumptive evidence of PE. Further trials are needed in this setting to study patients with hypercoagulable states.
